Family Story Reignites Debate Over Keto’s Promise for Mental Health

A family story can outrun the literature

Jan Ellison Baszucki’s case for keto in mental health starts with her son Matthew, who had a severe psychiatric crisis at 19 and was diagnosed with bipolar 1 disorder with psychotic features. After years of unstable treatment, the family learned about Harvard psychiatrist Christopher Palmer’s work on therapeutic ketogenic diets in late 2020, and Matthew began a medically supervised ketogenic regimen.

What happened next is the part that makes the story so powerful, and so easy to overread. According to Baszucki, Matthew’s symptoms cleared within four months and he has stayed in remission for more than five years. That recovery helped inspire the family to fund research, but the larger point is that a dramatic individual response is not the same thing as proof for everyone.

The public argument flared again after Robert F. Kennedy Jr. amplified claims that keto can cure schizophrenia or erase a bipolar diagnosis. His comments, made during a Tennessee tour promoting the administration’s dietary guidelines, drew criticism and fact-checks for overstating early findings. Palmer also pushed back, saying Kennedy overstated the evidence when he claimed to have “cured schizophrenia using keto diets,” a line that captures exactly where the hype starts to outrun the science.

What keto therapy actually is, and why psychiatrists are taking it seriously

Therapeutic ketogenic diet is not just “eating keto” in the social-media sense. In the psychiatric trials now underway, it means a high-fat, very low-carbohydrate, moderate-protein eating pattern designed to induce ketosis, usually under medical supervision. The Stanford pilot trial described the menu plainly: about 10% of calories from carbohydrates, 30% from protein, and 60% from fat.

That medical framing matters because keto is not a novelty in medicine. It has been used for more than a century in epilepsy, and later became a standard nonpharmacologic option for drug-resistant childhood epilepsy. That history is one reason some researchers argue psychiatry may now be at an earlier, analogous stage, where a treatment with real physiologic effects is still moving from case reports and small studies toward more rigorous testing.

For keto-curious readers, that distinction is everything. A ketogenic diet may be a plausible therapeutic tool in a clinical setting, but it is not the same thing as a wellness hack, and it is definitely not a substitute for the usual guardrails around serious psychiatric illness. The moment the conversation shifts from possible benefit to guaranteed cure, the debate stops being scientific and starts becoming sales pitch.

Where the evidence looks strongest right now

The strongest signal so far appears to be in bipolar disorder and schizophrenia, especially in people who also have metabolic abnormalities. Stanford Medicine reported a four-month pilot trial in 21 adults with schizophrenia or bipolar disorder and metabolic abnormalities, and the results were described as promising for both psychiatric and metabolic outcomes. That is encouraging, but it is still a pilot, which means it is useful for generating hypotheses, not settling them.

Stanford is now trying to push the field into something more definitive. ClinicalTrials.gov lists NCT06748950, a Stanford-sponsored randomized trial of ketogenic metabolic therapy in schizophrenia, bipolar disorder, and major depressive disorder, which is being set up to better assess quality of life across those diagnoses. ClinicalTrials.gov also lists NCT06920940, a 16-week open trial of ketogenic diet in youth with bipolar disorder that is testing mood, depression, inflammatory, metabolic, and executive-function outcomes.

There is also a practical real-world clue in the retrospective literature. A 2022 analysis in Frontiers in Psychiatry looked at 31 inpatients with major depressive disorder, bipolar disorder, or schizoaffective disorder who were placed on a ketogenic diet restricted to a maximum of 20 grams of carbohydrate per day, and it found the approach was feasible in a psychiatric-hospital setting. Feasibility is not efficacy, but in a field where adherence, medication burden, and metabolic side effects often collide, feasibility is not nothing.

Where the evidence is weakest, and where the hype gets ahead of the data

Major depressive disorder is the least developed part of the story. There are hints of potential benefit, but the evidence is thinner than it is for bipolar disorder and schizophrenia, and no one should confuse early-stage signals with a diagnosis-level cure. The broad claims that keto can remove schizophrenia or erase bipolar disorder go well beyond what the current research supports.

That is also why the growing trial count matters. A 2024 review summarized that roughly 20 psychiatric ketogenic clinical trials were underway, including eight randomized controlled trials, which is a sign that the field is moving beyond isolated anecdotes. The Baszucki family’s decision to fund research helped push this conversation into serious academic circles, but the next step has to be larger public funding so researchers can figure out who benefits, what the risks are, and how ketogenic therapy should fit into real-world care.

For now, the most honest read looks like this:

• The best-supported use case is adjunctive, medically supervised treatment in selected patients, especially in bipolar disorder and schizophrenia.
• The most dramatic stories, like Matthew’s, are meaningful but still anecdotal.
• The weakest point in the public conversation is any claim that keto is a cure.

That is the real split in this debate. The evidence gap is still wide, but it is no longer wide enough to dismiss the question outright. Keto may end up earning a place in metabolic psychiatry, yet the research will have to do the work that personal testimony cannot: show who benefits, by how much, and at what cost.